Daiichi Sankyo Co., Ltd. has been selected as one of the SX(Sustainability Transformation) Brand 2026, an annual designation jointly administered by the Ministry of Economy, Trade and Industry (METI) and the Tokyo Stock Exchange (TSE). This marks the Company's third consecutive selection, following its selection in 2024 and 2025.
Key factors contributing to this recognition include:
● A clear value creation story rooted in Patient Centricity, together with a strong competitive advantage and its distinctive position in the oncology field;
● Clear and specific resource allocation priorities, including focused investments in R&D, while positioning investment in human capital and initiatives related to non-financial capital, including DX/AI, and intellectual property-all of which underpin the Company's value creation-as key components of its business strategy; and
● Steady progress in strengthening a governance framework aligned with the Company's global growth, which underpins its value creation model and investment plan.
Daiichi Sankyo Group will continue to contribute to solving societal challenges and enhance corporate value in line with our Purpose, "Contribute to the Enrichment of Quality of Life Around the World."
■What is an SX brand?
SX is an initiative in which companies strive to improve long-term and sustainable corporate value by synchronizing the sustainability of society with their own while carrying out the necessary management and business reforms to achieve such synchronization. For more information on "SX Brands", please click here.
